MPR

MPR provides daily drug news and industry-supported drug information & education. Download our drug reference and clinical tools app today!

[MPR @eMPR]

All the notable drug pipeline updates that occurred in May in one easy-to-read table. #DrugsInThePipeline https://t.co/dkvPm8hI67

[MPR @eMPR]

A Trump executive order is calling for the CDC and its Advisory Committee to review a HHS assessment and to "take any appropriate steps to update the US childhood and adolescent vaccine schedule." #VaccineSchedule https://t.co/qI4FU5Azmk

[MPR @eMPR]

Adjuvant therapy for early breast cancer is granted Priority Review. Target decision date of November 30, 2026 set for the application. https://t.co/fMBcuKis2Z

[MPR @eMPR]

First postexposure COVID-19 prophylaxis gains FDA approval. A trial showed that Xocova significantly reduced the likelihood of developing symptoms following exposure by 67% compared with placebo. #COVID19 https://t.co/aVkiyIRkWl

[MPR @eMPR]

Afrezza Inhalation Powder is now approved for pediatric patients aged 6 years and older, providing a noninvasive mealtime insulin option. #Diabetes https://t.co/dTpGsAm1LQ

[MPR @eMPR]

Tremfya labelling updated to include data indicating the treatment inhibits the progression of structural joint damage in adults with active psoriatic arthritis. #PsoriaticArthritis https://t.co/IAT502IMsu

[MPR @eMPR]

🎧 New MPR Pod out now!
🔹 Novel Tx shows significant weight loss;
🔸 Hep delta virus Tx given accelerated approval;
🏪 Acne gel gains OTC designation;
🔹 Constipation Tx indication expanded; &
🔸 FDA extends review for camizestrant. #Podcast #PharmaPod
https://t.co/CTZvR9s0I5

[MPR @eMPR]

Study finds tirzepatide superior to intensified conventional care for mean changes in hemoglobin A1c, weight, and waist circumference. https://t.co/ozlFwHGiFh

[MPR @eMPR]

The FDA has extended the review for an investigational advanced breast cancer Tx Camizestrant after the Advisory Committee voted 6 to 3 against recommending approval. https://t.co/661yBC6Q8m

[MPR @eMPR]

Trial finds single consolidated infusion of Briumvi comparable to current schedule of multiple doses. #Pipeline #MultipleSclerosis https://t.co/ERGeoDQygw

[MPR @eMPR]

NIAID officials barred from communicating with the WHO. They can attend virtual WHO meetings in small groups and only in a “listening capacity." #Policy #InfectiousDiseases https://t.co/rl51ZCcQAN

[MPR @eMPR]

More uncertainty at HHS as the head of the National Institute for Allergy and Infectious Diseases steps down. The reason for the departure is unknown. https://t.co/fa5Ca1NNCg

[MPR @eMPR]

FDA approves first treatment for chronic hepatitis delta virus. #DrugApproval #Hepatitis
https://t.co/U7vool68D6

[MPR @eMPR]

A 20-year-old woman presents with a recurrent, well-defined patch on the right side of her chest that appeared earlier in the day. Can you make the correct diagnosis? Take this week's Clinical Challenge! #Dermatology https://t.co/hjZR0fdwn5

[MPR @eMPR]

A late-stage study of fianlimab and cemiplimab as first-line therapy for unresectable or metastatic melanoma missed its primary efficacy endpoint.
https://t.co/48oDWRvE0i

[MPR @eMPR]

Amazon customers may have received expired emergency contraception. Several lots of expired levonorgestrel were delivered between January and April. https://t.co/ndRMMOryAD

[MPR @eMPR]

High-risk of cross-border spread for current ebola outbreak, declares WHO. The US withdrew from WHO under the Trump administration earlier this year. https://t.co/2M9kPkGFY5

[MPR @eMPR]

New hypertension treatment Baxfendy inhibits aldosterone synthase resulting in decreased plasma aldosterone and a subsequent reduction in blood pressure. https://t.co/HnYvpvjF4O

[MPR @eMPR]

Tecentriq becomes the first immunotherapy approved for a ctDNA-guided adjuvant indication in muscle-invasive bladder cancer. #DrugApprovals
https://t.co/UbSRM3ORQT

[MPR @eMPR]

New #Crysvita dosing guidance for adults with XLH who experience serum phosphorus levels below the normal range after the initial treatment period.
https://t.co/q8Gb2VITna